Brain insulin sensitivity determines body weight and fat distribution

April 24, 2020

Just where fat is deposited in the body and to what degree a person may benefit from a lifestyle intervention depends, among other things, on how sensitive the brain is to insulin. If the person's brain responds sensitively to the hormone, a significant amount of weight can be lost, unhealthy visceral fat reduced, and the weight loss can be maintained over the long term. However, If the person's brain responds only slightly or not at all to insulin, the person only loses some weight at the beginning of the intervention and then experiences weight regain. Over the long term, the visceral fat also increases. These are the results of a long-term study by the German Center for Diabetes Research (DZD), Helmholtz Zentrum München and Tübingen University Hospital which has now been published in Nature Communications.

To which extent body fat has an unhealthy effect depends primarily on where it is stored. If fat accumulates in the abdomen, this is particularly unfavorable. This is because the visceral fat releases numerous neurotransmitters that affect blood pressure, influence the secretion of the hormone insulin and can cause inflammation. This increases the risk of diabetes, cardiovascular disease and certain types of cancer. The subcutaneous fat which accumulates on the buttocks, thighs and hips has no adverse health effects. However, it is still unclear why fat storage does not occur in the same place in all people. Studies in the Tübingen Lifestyle Intervention Program (TULIP) [1] suggest that brain insulin responsiveness could play an important role here. They showed that people with a high insulin sensitivity in the brain benefit significantly more from a lifestyle intervention with a diet rich in fiber and exercise than people with insulin resistance in the brain. Not only did they lose more weight, they also had a healthier fat distribution. But how does insulin sensitivity affect the distribution of body fat and weight in the long term? Researchers from the German Center for Diabetes Research (DZD), Helmholtz Zentrum München and Tübingen University Hospital investigated this question in a long-term study. For this purpose, they recorded the follow-up data of 15 participants over a period of nine years, in which the insulin sensitivity in the brain was determined by magnetoencephalography before the start of a 24-month lifestyle intervention.

High insulin sensitivity associated with reduction in visceral fat and weight

It was found that insulin action in the brain not only determines body weight, but also the distribution of fat in the body. "Subjects with high insulin sensitivity in the brain benefited from the lifestyle intervention with a pronounced reduction in weight and visceral fat. Even after the lifestyle intervention had ended, they only regained a small amount of fat during the nine-year follow-up," said the head of the study, Professor Martin Heni from Tübingen University Hospital. In contrast, people with brain insulin resistance only showed a slight weight loss in the first nine months of the program. "Afterwards, their body weight and visceral fat increased again during the following months of lifestyle intervention," said first author PD Dr. Stephanie Kullmann from the IDM.

Since the insulin action in the hypothalamus is crucial for the regulation of peripheral energy metabolism, the researchers also investigated how insulin sensitivity in this area of the brain is related to the distribution of body fat. For this purpose, they examined a cross-sectional cohort of 112 participants. The analysis of the data showed that people with high insulin sensitivity in the hypothalamus form little visceral fat. However, insulin sensitivity has no influence on the mass of subcutaneous fat.

Our study reveals a novel key mechanism that regulates fat distribution in humans. Insulin sensitivity in the brain determines where fat is deposited, "said Heni, summarizing the results. Since visceral fat not only plays a role in the development of type 2 diabetes, but also increases the risk of cardiovascular disease and cancer, the study results may also open up new approaches for treatment options beyond metabolic diseases. The researchers in Tübingen are already working on new therapies to abolish insulin resistance in the brain and thus have a beneficial effect on body fat distribution.
-end-
Original Publication: Kullmann et al. (2020): Brain insulin sensitivity is linked to adiposity and body fat distribution. Nature Communications, DOI: https://doi.org/10.1038/s41467-020-15686-y

Scientific contact:

Prof. Dr. med. Martin Heni
Tübingen University Hospital, Internal Medicine IV
Otfried Müller Straße 10
72076 Tübingen
Phone: +49 (0)7071 29-82714
email: martin.heni@med.uni-tuebingen.de

Media contact:

Birgit Niesing
German Center for Diabetes Research
Ingolstädter Landstraße 1
85764 Neuherberg
Phone: 089-3187-3971
email: niesing@dzd-ev.de

The German Center for Diabetes Research (DZD) e.V. is one of six German Centers for Health Research. It brings together experts in the field of diabetes research and combines basic research, epidemiology and clinical application. By adopting an innovative, integrative approach to research, the DZD aims to make a substantial contribution to the successful, personalized prevention, diagnosis and treatment of diabetes mellitus. The members of the association are Helmholtz Zentrum München - German Research Center for Environmental Health, the German Diabetes Center (DDZ) in Düsseldorf, the German Institute of Human Nutrition (DIfE) in Potsdam-Rehbrücke, the Institute of Diabetes Research and Metabolic Diseases of Helmholtz Zentrum München at the University of Tübingen, and the Paul Langerhans Institute Dresden of Helmholtz Zentrum München at the University Medical Center Carl Gustav Carus of TU Dresden, associated partners at the universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich, and other project partners. Further information:: http://www.dzd-ev.de

As German Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the diagnosis, therapy and prevention of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The head office of the center is located in Neuherberg to the north of Munich. Helmholtz Zentrum München has approximately 2300 staff members and is a member of the Helmholtz Association, a German research organization comprised of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de

Founded in 1805, Tübingen University Hospital is one of the leading centers of German university medicine. As one of the 33 university hospitals in Germany, it contributes to the successful combination of high-performance medicine, research and teaching. Well over 400,000 inpatients and outpatients from all over the world benefit annually from this combination of science and practice. The clinics, institutes and centers unite all specialists under one roof. The experts work together across disciplines and offer every patient optimal treatment based on the latest research results. Tübingen University Hospital conducts research for better diagnoses, therapies and chances of cure, many new treatment methods are clinically tested and applied here. Neurosciences, oncology, immunology, infection research, vascular medicine and diabetes research are the main areas of research in Tübingen. The University Hospital is a reliable partner in four of the six German Centers for Health Research initiated by the German government. http://www.medizin.uni-tuebingen.de

Deutsches Zentrum fuer Diabetesforschung DZD

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.